Clinical impact of positron emission tomography by coincidence system with 18F-FDG on therapeutic decision-making of patients with ischemic cardiomyopathy after myocardial infarction;Impacto clínico da tomografia por emissão de pósitrons realizada pelo sistema de coincidência com FDG-18F, na conduta terapêutica de pacientes com cardiopatia isquêmica pós-infarto do miocárdio

Arquivos Brasileiros de Cardiologia

Volumn 86, Issue 5, 2006, Pages 337-345

  Martins Felix, Renata Christian ^a,b   Correa, Patrícia Lavatori ^a   De Azevedo, Jader Cunha ^a   Da Rocha Dohmann, Hans Fernando ^a   Mesquita, Evandro Tinoco ^a   Mesquita, Cláudio Tinoco ^a  

^a HOSPITAL PRÓ CARDÍACO   (Brazil)

^b NONE   (Brazil)

Author keywords

Coincidence system; Ischemic cardiomyopathy; Myocardial viability; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MALE; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; PHYSICIAN; POSITRON EMISSION TOMOGRAPHY; QUESTIONNAIRE;

DECISION MAKING, COMPUTER-ASSISTED; ELECTROCARDIOGRAPHY; FEMALE; FLUORODEOXYGLUCOSE F18; HEART; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REVASCULARIZATION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33744950427     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2006000500003     Document Type: Article

References (44)

1. Segall G. Assessment of myocardial viability by positron emission tomography. Nucl Med Commun .2002; 23: 323-30.
2. Kostakoglu L, Agress H, Goldsmith SF. Clinical role of FDG PET in evaluation of cancer patients. Radiographics .2003; 23: 315-40.
3. Hoffman JM, Welsh-Bohmer KA, Hanson M , Gain B, Hullette C, Earl N et al. FDG PET Imaging in patients with pathologically verified dementia. J Nucl Med .2000; 41: 1920-8.
4. Dohmen C, Bosche B, Graf , Staub F, Kracht L, Sobesky J et al. Prediction of malignanat course in MCA infarction by PET and microdialysis. Stroke. 2003; 34: 2152-8.
5. Cyclotron Accelerators Center.[web site on the Internet].São Paulo: IPEN;1999.[cited 2004 Nov 10].Available from:http://www.ipen.br/biblioteca/ progress/cyclotron.htm
6. Ansari M, Massie BM. Heart failure: how big is the problem? Who are the patients? What does the future hold? Am Heart J .2003; 146:1-4.
7. Marwick TH. The viable myocardium: epidemiology, detection and clinical implications. Lancet .1998; 351: 815-9.
8. Gheorghiade M, Bonow R. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation .1998; 97: 282-9.
9. Hellerman JP, Goraya TY, Jacobsen SJ , Weston AS, Reeder GS, Gersh B et al. Incidence of heart failure after myocardial infarction: is it changing over time? Am J Epidemiol .2003; 157: 1101-07.
10. Wijins W, Vatner SF, Camici PG. Hibernating Myocardium. N Engl J Med 1998; 339: 173-81.
11. Raynes RB, Devereaux PJ, Guyatt GH. Clinical expertise in the era of evidence-based medicine and patient choice. EBM 2002; 7: 36-8.
12. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002; 39: 1151-8.
13. Dilsizian V, Bacharach SL, Khin MM, Smith MF. Fluorine-18-deoxyglucose SPECT and coincidence imaging for myocardial viability: clinical and technologic issues. J Nucl Cardiol .2001; 8: 75-88.
14. Fitzgerrald J, Parker JA, Danias PG. F-18 fluoro deoxyglucose SPECT for assessment of myocardial viability. J Nucl Cardiol 2000; 7: 382-7.
15. 18F-fluordesoxyglucose single photon emission computed tomography: can it replace PET and thallium SPECT for the assessment of myocardial viability? Circulation .1998; 97: 843-50.
16. th ed. Boston, MA: Little Brown, 1964.
17. Campeau L. Grading of angina pectoris. Circulation .1976; 54: 522-3.
18. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK et al. Standardized Myocardial Segmentation and Nomenclature for Tomographic Imaging of Heart. A statement for health care professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation . 2002; 105: 539-42.
19. Bacharach SL, Bax JJ, Case J , Delbeke D, Kurdziel KA, Martin WH et al. PET myocardial glucose metabolism and perfusion imaging: Part 1 - Guidelines for data patient preparation and data acquisition. J Nucl Cardiol .2003; 10: 543-56.
20. Chen EQ, MacIntyre WJ, Go R, Brunken RC, Saha GB, Wong CY et al Myocardial viability studies using fluorine-18-FDG SPECT: a comparison with fluorine-18-FDG PET. J Nucl Med 1997; 38: 582-6.
21. Hellermann JP, Jacobsen SJ, Redfield MM , Reeder GS, Weston AS, Roger VL. Heart failure after myocardial infarction: clinical presentation and survival. Eur J Heart Fail .2005; 7: 119-25.
22. Mezulín J, Cerny J, Spinarova L, Toman J, Grach L, Stetka F et al. Prognosis in patients with chronic coronary artery disease and severe left ventricular dysfunction: the importance of myocardial viability. Eur J Heart Fail .2003; 5: 85-93.
23. Hass F, Haehnel CJ, Picker W , Nekolla S, Martinoff S, Meisner H et al. Preoperative positron emission tomograhic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol .1997; 30: 1693-700
24. Bax JJ, Visser FC, Poldermans D , Elhendy A, Boersma E, Visser CA et al. Prognostic value of perfusion-FDG mismatch in ischemic cardiomyopathy. J Nucl Cardiol .2002; 9: 675-77.
25. Auerbach MA, Schöder H, Hoh C , Gambhir SS, Yaghoubi S, Sayre JW et al. Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy. Circulation .1999; 99: 2921-6.
26. Talbot JN, Rain JD, Meignan M, Askienazaky S, Grall Y,Bok B et al. Impact of 18F-FDG-PET on medical decision making in oncology: evaluation by referring physicians during the opening year. Bull Cancer .2002; 89: 313-21.
27. Meta J, Seltzer M, Schiepers C , Silverman DH, Ariannejad M, Gamhir SS et al. Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective. J Nucl Med .2001; 42: 586-90.
28. Yap CS, Seltzer MA, Schiepers C ,Gambhir SS, Rao J, Phelps ME et al. Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective. J Nucl Med .2001; 42: 1334-7.
29. Schoder H, Meta J, Yap C , Ariannejad M, Rao J, Phelps ME et al. Effect of whole-body 18F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med .2001; 42: 1139-43.
30. Seltzer MA, Yap CS, Silverman DH, Meta J, Schiepers C, Phelps ME et al. The impact of PET on the management of lung cancer: the referring physician's perspective. J Nucl Med 2002; 43: 752-6.
31. Grahek D, Montravers F, Mayaud C , Regnard JF, Kerrou K, Younsi N et al. Positron emission tomography (PET) with 18F-FDG in bronchopulmonary cancer and its impact on medical decision at the time of the diagnosis, staging or recurrence evaluation. Rev Pneumol Clin .2001; 57: 393-403.
32. Kantorova I, Lipska L, Belohlvek O , Visokai V, Trubac M, Schneiderova M. Routine 18F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med. 2003; 44: 1784-88.
33. Herder GJ, Van Tinteren H, Comans EF , Holkstra OS, Teule GJ, Postmus PE et al. Prospective use of serial questionnaires to evaluate the therapeutic efficacy of 18F-fluordeoxygluse (FDG) positron emission tomography (PET) in suspected lung cancer. Thorax .2003; 58: 47-51.
34. Tian M, Koyama K, Zhang H , Oriuchi N, Higuchi T, Endo K. Assessment of myocardial viability with a positron coincidence gamma camera using fluordeoxyglucose in comparison with dedicated PET. Nucl Med Commun .2003; 24: 367-74.
35. 18F-fluorodeoxyglucose Imaging with a dual-head coincidence gamma camera for detection of myocardial viability. J Nucl Med .1999; 40: 1884-92.
36. Lee, K, Marwick TH, Cook S , Go RT, Fix JS,James KB et al. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction:relative efficacy of medical therapy and revascularization Circulation 1994; 90: 2687-94.
37. Di Carli MF, Davidson M, Little R , Khannaady FV, Brunken RC. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol .1994; 73: 527-33.
38. Eitzman D, Al-Aouar Z, Kanter HL, Vom Dahl J, Kirsch M, Deeb GM et al. Clinical outcome of patients with advanced coronary artery disease. J Am Coll Cardiol .1992; 20: 559-65.
39. Yoshida K, Gould LK. Quantitative relation of myocardial infarction size and myocardial viability by positron emission tomography to left ventricular ejection fraction and 3-year mortality with and without revascularization. J Am Coll Cardiol 1993; 22: 984-97.
40. Schinkel AFL, Bax JJ, Boersma E , Elhendy A, Vourvouri EC, Roelandt JR et al. Assessment of residual myocardial viability in regions with chronic electrocardiographic Q-wave infarction. Am Heart J.2002; 144: 865-9.
41. Marwick TH, Zuchowskic C, Lauer MS , Secknus MA,Williams J, Lytle BW. Functional status and quality of life in patients with heart failure undergoing coronary bypass surgery after assessment of myocardial viability. J Am Coll Cardiol. 1999; 33: 750-8.
42. Beanlands RSB, Ruddy TD, deKemp RA , Iwanochko RM, Coates G, Freem,na M et al. Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J Am Coll Cardiol. 2002; 40: 1735-43.
43. Di Carli MF, Maddahi J, Rokhsar SBA , Schelbert HR, Bianco-Batles D, Brunken RC et al. Long-term survival of patients with coronary artery disease and left ventricular dysfunction: implications for the role of myocardial viability assessment in management decisions. J Thorac Cardiovasc Surg .1998; 116: 997-1004.
44. Hurrell DG, Milavetz J, Hodge DO, Gibbons RJ. Infarct size determination by technetium 99m sestamibi single-photon emission computed tomography predicts survival in patients with chronic coronary artery disease. Am Heart J .2000; 140: 61-6.